Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Westaby D, Fenor de La Maza MLD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, Sharp A. Westaby D, et al. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:131-153. doi: 10.1146/annurev-pharmtox-052220-015912. Epub 2021 Aug 24. Annu Rev Pharmacol Toxicol. 2022. PMID: 34449248 Review.
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp A. Sowalsky AG, et al. Among authors: jimenez vacas jm. Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851. Clin Cancer Res. 2022. PMID: 35695870 Free PMC article.
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Paschalis A, Welti J, Neeb AJ, Yuan W, Figueiredo I, Pereira R, Ferreira A, Riisnaes R, Rodrigues DN, Jiménez-Vacas JM, Kim S, Uo T, Micco PD, Tumber A, Islam MS, Moesser MA, Abboud M, Kawamura A, Gurel B, Christova R, Gil VS, Buroni L, Crespo M, Miranda S, Lambros MB, Carreira S, Tunariu N, Alimonti A, Al-Lazikani B, Schofield CJ, Plymate SR, Sharp A, de Bono JS; , SU2C/PCF International Prostate Cancer Dream Team. Paschalis A, et al. Cancer Res. 2021 Feb 15;81(4):1087-1100. doi: 10.1158/0008-5472.CAN-20-1807. Cancer Res. 2021. PMID: 33822745 Free PMC article.
Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
Jiménez-Vacas JM, Montero-Hidalgo AJ, Gómez-Gómez E, Sáez-Martínez P, Fuentes-Fayos AC, Closa A, González-Serrano T, Martínez-López A, Sánchez-Sánchez R, López-Casas PP, Sarmento-Cabral A, Olmos D, Eyras E, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. Transl Res. 2023 Mar;253:68-79. doi: 10.1016/j.trsl.2022.08.016. Epub 2022 Sep 9. Transl Res. 2023. PMID: 36089245 Free article.
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9. Mol Cancer. 2017. PMID: 28851363 Free PMC article.
Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Fuentes-Fayos AC, Martínez-López A, Sánchez-Sánchez R, González-Serrano T, López-Ruiz DJ, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. Transl Res. 2019 Oct;212:89-103. doi: 10.1016/j.trsl.2019.07.001. Epub 2019 Jul 9. Transl Res. 2019. PMID: 31344348
Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gómez-Gómez E, Fuentes-Fayos AC, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Pedraza-Arévalo S, González-Serrano T, Reyes O, Martínez-López A, Sánchez-Sánchez R, Ventura S, Yubero-Serrano EM, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. EBioMedicine. 2020 Jan;51:102547. doi: 10.1016/j.ebiom.2019.11.008. Epub 2020 Jan 3. EBioMedicine. 2020. PMID: 31902674 Free PMC article.
SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC, Pérez-Gómez JM, G-García ME, Jiménez-Vacas JM, Blanco-Acevedo C, Sánchez-Sánchez R, Solivera J, Breunig JJ, Gahete MD, Castaño JP, Luque RM. Fuentes-Fayos AC, et al. J Exp Clin Cancer Res. 2022 Jan 27;41(1):39. doi: 10.1186/s13046-022-02241-4. J Exp Clin Cancer Res. 2022. PMID: 35086552 Free PMC article.
35 results